Loading...
By The Editors
The FDA has approved blinatumomab (Blincyto) as an immunotherapy for Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia.
Blinatumomab works by connecting the CD19 protein on the surface of B-cell lymphoblasts with the CD3 protein on T-cell lymphocytes.
Comment
LINK(S):
FDA news release (Free)
Background: NEJM Journal Watch General Medicine summary on blinatumomab (Your NEJM Journal Watch registration required)